Compare JACK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JACK | MNPR |
|---|---|---|
| Founded | 1951 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 260.2M | 403.4M |
| IPO Year | 1994 | 2019 |
| Metric | JACK | MNPR |
|---|---|---|
| Price | $12.59 | $61.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $23.47 | ★ $101.42 |
| AVG Volume (30 Days) | ★ 760.4K | 145.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.48% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,465,314,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.30 | $26.06 |
| 52 Week High | $32.51 | $105.00 |
| Indicator | JACK | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 21.81 | 58.07 |
| Support Level | N/A | $50.92 |
| Resistance Level | $20.96 | $89.51 |
| Average True Range (ATR) | 0.64 | 3.09 |
| MACD | -0.25 | 1.10 |
| Stochastic Oscillator | 6.59 | 91.62 |
Jack In The Box Inc operates quick-service restaurants and fast-casual restaurants across various states in the United States of America. Its core business includes the Jack in the Box hamburger chain, known for a broad menu that features hamburgers, tacos, sandwiches, salads, and breakfast items. The company also operates the Del Taco brand, which offers a variety of both Mexican and American favorites such as burritos and fries. These foods are available with the option of customization as per customer requirements. The company also offers catering and delivery services to its customers. Jack in the Box and Del Taco restaurant brands are the two reportable operating segments, of which, Jack in the Box generates maximum revenue for the company.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.